US2008214453A1PendingUtilityA1

Methods for treating inflammation

65
Assignee: UNIV COLUMBIAPriority: Nov 22, 1996Filed: Aug 20, 2007Published: Sep 4, 2008
Est. expiryNov 22, 2016(expired)· nominal 20-yr term from priority
Inventors:David M. SternKevan C. HeroldShi Du YanAnn Marie SchmidtIra Lamster
A61K 31/00A61K 2039/505A61P 29/00A61K 38/1774C07K 16/18
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount effective to inhibit binding of advanced glycation endproducts (AGEs) to RAGE thereby treating inflammation in the subject. The present invention also provides for a method for treating inflammation in a subject which comprises administering to the subject an agent in an amount effective to inhibit the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject.

Claims

exact text as granted — not AI-modified
1 . A method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) (SEQ ID NO:1) in an amount effective to treat inflammation in the subject. 
     
     
         2 . A method for treating inflammation in a subject which comprises administering to the subject a polypeptide consisting essentially of the V-domain (SEQ ID NO:2) of receptor for advanced glycation endproduct (RAGE) in an amount effective to treat inflammation in the subject. 
     
     
         3 . A method for treating inflammation in a subject which comprises administering to the subject an agent in an amount which inhibits the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject. 
     
     
         4 - 25 . (canceled)

Join the waitlist — get patent alerts

Track US2008214453A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.